Literature DB >> 1906289

Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection.

M von Sydow1, A Sönnerborg, H Gaines, O Strannegård.   

Abstract

Serum samples of 120 patients in different stages of chronic human immunodeficiency virus type 1 (HIV-1) infection, 11 patients with primary HIV-1 infection (PHI), and 49 HIV-1 seronegative homosexual men were analyzed for tumor necrosis factor-alpha (TNF-alpha), interferon-alpha (IFN-alpha), and HIV-1 p24 antigen. Increased levels of IFN-alpha and TNF-alpha were found in some, but not all, cases with PHI. During progressing disease IFN-alpha occurred in serum with increasing frequency and concentration. Raised levels of TNF-alpha were found in all stages of chronic infection, but were less common in patients with AIDS than were raised levels of IFN-alpha. The levels of the two substances were not correlated. There was a correlation between IFN-alpha, but not TNF-alpha, and the occurrence of HIV-1 p24 antigen in serum. These results suggest that IFN-alpha and TNF-alpha are induced by different agents during HIV-1 infection. The findings would be consistent with the hypothesis that IFN-alpha and TNF-alpha are counteracting forces that have important down- and upregulatory effects, respectively, on HIV-1 replication in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906289     DOI: 10.1089/aid.1991.7.375

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  90 in total

1.  Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.

Authors:  Jean-Philippe Herbeuval; Jakob Nilsson; Adriano Boasso; Andrew W Hardy; Michael J Kruhlak; Stephanie A Anderson; Matthew J Dolan; Michel Dy; Jan Andersson; Gene M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women.

Authors:  Pascal Azar; José Enrique Mejía; Claire Cenac; Arnoo Shaiykova; Ali Youness; Sophie Laffont; Asma Essat; Jacques Izopet; Caroline Passaes; Michaela Müller-Trutwin; Pierre Delobel; Laurence Meyer; Jean-Charles Guéry
Journal:  JCI Insight       Date:  2020-06-18

3.  Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy.

Authors:  Adriana A Byrnes; David M Harris; Sowsan F Atabani; Beulah P Sabundayo; Susan J Langan; Joseph B Margolick; Christopher L Karp
Journal:  J Leukoc Biol       Date:  2008-09-19       Impact factor: 4.962

4.  Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections.

Authors:  Andrea R Stacey; Philip J Norris; Li Qin; Elizabeth A Haygreen; Elizabeth Taylor; John Heitman; Mila Lebedeva; Allan DeCamp; Dongfeng Li; Douglas Grove; Steven G Self; Persephone Borrow
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

5.  Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation.

Authors:  O M Howard; K A Clouse; C Smith; R G Goodwin; W L Farrar
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

6.  Serum adipokines and HIV viral replication in patients undergoing antiretroviral therapy.

Authors:  Victoria Aramă; Cătălin Tilişcan; Daniela Adriana Ion; Raluca Mihăilescu; Daniela Munteanu; Anca Streinu-Cercel; Ana Maria Tudor; Adriana Hristea; Viorica Leoveanu; Ioana Olaru; Stefan Sorin Aramă
Journal:  Germs       Date:  2012-03-01

7.  Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever.

Authors:  Lauren M Smith; Lisa E Hensley; Thomas W Geisbert; Joshua Johnson; Andrea Stossel; Anna Honko; Judy Y Yen; Joan Geisbert; Jason Paragas; Elizabeth Fritz; Gene Olinger; Howard A Young; Kathleen H Rubins; Christopher L Karp
Journal:  J Infect Dis       Date:  2012-12-18       Impact factor: 5.226

8.  Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression.

Authors:  Gareth A D Hardy; Scott F Sieg; Benigno Rodriguez; Wei Jiang; Robert Asaad; Michael M Lederman; Clifford V Harding
Journal:  Blood       Date:  2009-03-19       Impact factor: 22.113

9.  HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha.

Authors:  Andrew W Hardy; David R Graham; Gene M Shearer; Jean-Philippe Herbeuval
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

10.  Effects of type I interferons on Friend retrovirus infection.

Authors:  Nicole Gerlach; Simone Schimmer; Siegfried Weiss; Ulrich Kalinke; Ulf Dittmer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.